Kymab: Sanofi to buy biopharmaceutical firm Kymab for up to $1.45bn

As per terms of the deal, Kymab will secure an upfront payment of up to $1.1bn from Sanofi. Kymab is also eligible to secure up to $350m based The post Sanofi to buy biopharmaceutical firm Kymab for up to $1.45bn appeared first on Pharmaceutical Business review.